Table 1 Descriptive analysis of demographic, clinical and laboratory data of all admitted cancer patients with COVID-19 diagnosis
From: Role of chest CT scan in patients with preexisting cancer and COVID-19 pneumonia
Variable | All cancer 266 |
|---|---|
Age—Mean (± SD) | 56.48 (18.59) |
Duration of stay (day)—Mean (± SD) | 13.00 (15.20) |
Oxygen saturation—Mean (± SD) | 90.41(8.00) |
Sex | |
Female | 125 (46.99%) |
Male | 141 (53.01%) |
Comorbidities | |
Diabetic | 67 (25.19%) |
Hypertension | 75 (28.20%) |
Cardiovascular diseases | 50 (18.80%) |
Chronic kidney diseases | 36 (13.53%) |
Lung diseases | 31 (11.65%) |
Liver diseases | 10 (3.76%) |
Severity | |
ICU admission | 104 (39.10%) |
Intubation | 68 (25.56%) |
Dead | 88 (33.08%) |
Reverse transcriptase-Polymerase Chain Reaction (RT-PCR) | |
Negative | 55 (20.68%) |
Positive | 183 (68.80%) |
Not done | 28 (10.53%) |
Type of cancer | |
Hematologic** | 70 (26.32%) |
Lung | 14 (5.26%) |
Breast | 28 (10.53%) |
Gastrointestinal | 78 (29.32%) |
Other | 76 (28.57%) |
Stage | |
Local | 11 (4.14%) |
Metastatic | 78 (29.32%) |
Unknown | 177 (66.54) |
Oncologic treatment | |
Surgery | 115 (43.23%) |
Chemotherapy | 174 (65.41%) |
Radiotherapy | 77 (28.95%) |
Target or endocrine therapy | 2 (0.75%) |
Immunotherapy | 1 (0.38%) |
Hormonotherapy | 11 (4.14%) |
Last oncologic treatment interval (Month) | 11.02 (± 39.12) |